Recent reports indicate that the measurement of serum p62/SQSTM1 levels has the potential to serve as a biomarker for the diagnosis of patients with steatosis and inflammation, indicative of NASH stage [89]. Here, SQSTM1 is linked to metabolic dysfunction-associated steatohepatitis.